Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Hostname: page-component-559fc8cf4f-28jzs Total loading time: 0.282 Render date: 2021-03-04T04:26:51.225Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }
EnglishFrançais
CNS Spectrums CNS Spectrums

Article contents

Studies of Carbamazepine Extended-Release Capsules in Bipolar Disorder

Published online by Cambridge University Press:  08 April 2017

Richard H. Weisler
Get access
Rights & Permissions[Opens in a new window]

Extract

This discussion reviews data from two 3-week, double-blind, placebo-controlled pivotal trials of carbamazepine extended release capsules (CBZ ERC; SPD417.301 and SPD417.304); pooled results from these trials; data from a 3-week, double-blind, placebo-controlled trial in lithium non-responders or non-tolerators (SPD417.302); and additional supportive data from a 6-month, open-label, extension trial (SPD417.303). In addition, information on a retrospective chart review of 600 adolescent and adult bipolar patients on CBZ ERC is presented.

In the first large double-blind, placebo-controlled study assessing CBZ ERC in acute mania, manic and mixed bipolar patients from multiple centers were hospitalized and all medications were discontinued. After reaching a stable baseline 2–5 days later, the patients were randomized to CBZ ERC (n=101; 59% with mixed states) or placebo (n=103; 47% with mixed states) for 3 weeks. An aggressive initial titration schedule was implemented, beginning with 200 mg BID and increased by 200 mg/day until good clinical response was achieved or the patient could not tolerate the dosage. Many patients were taking 1,200–1,600 mg/day by the end of week 1. Efficacy was assessed using the Young Mania Rating Scale (YMRS). The Clinical Global Impressions (CGI) scale and the Hamilton Rating Scale for Depression (HAM-D) were also followed.

Type
Research Article
Information
CNS Spectrums , Volume 10 , Issue 6 , June 2005 , pp. 3 - 5
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below.
If you should have access and can't see this content please contact technical support.

References

1.Weisler, RH, Keck, PE Jr, Swann, AC, et al.Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005;66(3):323–330.CrossRefGoogle ScholarPubMed
2. Data on file, Shire Pharmaceutical Development.Google Scholar
3.Weisler, RH, Kalali, AH, Ketter, TA; SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004;65(4):478–484.CrossRefGoogle ScholarPubMed
4.Weisler, RH, Kalali, AH, Ketter, TA. Carbamazepine extended release treatment of manic and mixed symptoms. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
5.Keck, PE Jr, Marcus, R, Tourkodimitris, S, et al.A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9):1651–1658.CrossRefGoogle ScholarPubMed
6.Keck, PE Jr, Versiani, M, Potkin, S, et al.Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741–748.CrossRefGoogle ScholarPubMed
7.Jones, MW, Huizar, K. Quetiapine monotherapy for acute mania associated with bipoler disorder (STAMP 1 and STAMP 2). Poster presented at: The 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA. Abstract NR432.Google Scholar
8.Tohen, M, Sanger, TM, McElroy, SL, et al.Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156(5):702–709.Google ScholarPubMed
9.Tohen, M, Jacobs, TG, Grundy, SL, et al.Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000;57(9):841–849.CrossRefGoogle Scholar
10.Hirschfeld, RMA, Keck, PE, Karcher, K, Kramer, ML, Grossman, F. Rapid antimanic effect of risperidone monotherapy: a three-week, multicenter, randomized, double-blind, placebo-controlled trial. Poster presented at: The 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA. Abstract NR182.Google Scholar
11.Ketter, TA, Kalali, AH, Weisler, RH; SPD417 Study Group. A 6-month, multi-center, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004;65(5):668–673.CrossRefGoogle ScholarPubMed
12.Weisler, RH, Keck, PE Jr, Ketter, TA, Swann, AC, Kalali, AH, Cutler, AJ. Efficacy of switching to extended-release carbamazepine in bipolar disorder. Poster presented at: 158th Annual Meeting of the AMerican Psychiatic Asociation; May 21-26, 2005; Atlanta, GA.Google Scholar
13.Ginsberg, LD, Data on file, Red Oak Psychiatry Associates.Google Scholar

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 9 *
View data table for this chart

* Views captured on Cambridge Core between 08th April 2017 - 4th March 2021. This data will be updated every 24 hours.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Studies of Carbamazepine Extended-Release Capsules in Bipolar Disorder
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Studies of Carbamazepine Extended-Release Capsules in Bipolar Disorder
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Studies of Carbamazepine Extended-Release Capsules in Bipolar Disorder
Available formats
×
×

Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *